associated with spondyloarthritis (including also IBD) were the most frequent (68 patients, 61%). Focusing on this group, 57.4% were male with a mean age of 49±15.8 years. 73.5% were HLAB27 positive and 76% had radiologic sacroiliitis. In 24 patients (35.3%) the diagnosis of spondyloarthritis was made after the anamnesis in the uveitis unit. The diagnosis was already known in the other cases. The spondyloarthritis subtypes are described in the table.
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Diagnosis n (%)
Ankylosing spondylitis 33 (48.5) Non radiographic axial spondyloarthritis 13 (19.1) Psoriatic arthritis 5 (7.4) IBD spondyloarthritis 5 (7.4) Peripheral spondyloarthritis 4 (5.9) Juvenile idiopathic arthritis 4 (5.9) IBD (without Joint involvement) 3 (4.4) Reactive arthritis 1 (1.5) Total 68 (100) According to the anatomical distribution, 95.6% were anterior uveitis (AU), followed by the intermediate and posterior ones (1,5% both). 85.3% has unilateral involvement and 10.3% bilateral. Relapsing acute AU was the most frequent pattern (73.5%), followed by non-relapsing acute AU (16.2%) and chronic AU (7.4%). 24 patients (35.3%) required treatment with DMARD to achieve uveitis control. The most commonly used drugs were salazopyrine (7 patients), methotrexate (6 patients), mycophenolate (1), and in another 6 patients anti-TNF treatment was started or the previous dose of the biological was adjusted. The visual acuity (VA) was not perfect (VA =1 in both eyes) in 35% in the first collected visit. 28% (19 patients) had cataract, and 19% (13) Background: The term spondyloarthritis (SpA) encompass a group of crhonic inflammatory disease with predominant axial involvement. Anti-TNF therapy (AT) has stirred up the management of these diseases. Nevertheles, according to nationwide registries of the drug continuation rate in several countries, the rate of treatment failure is considerable. Nowdays there are insufficient data to evaluate the differences between responders (Resp-AT) and non-responders (Nonresp-AT) to anti-TNF therapy. Objectives: To compare the main sociodemographic, clinical and analytical features at baseline, after 6 months of treatment and at the end of the first anti-TNF therapy of responders to a first anti-TNF therapy and non-responders to several anti-TNF therapies form our cohort of patients diagnosed with SpA. We also analized the association between drug levels (DL) and antidrug antibody (ADA) in non-responders to several anti-TNF. Methods: 181 patients were included, 155 (85%) kept receiving their first AT therapy (responders) and 26 (15%) had discontinued at least two different AT therapies. The main demographic features, disease activity (BASDAI, ASDAS, CRP and ESR) were measured at baseline, after 6 months (v-6) and when the first AT was discontinued. Serum drug levels and/or ADA were measured at drug discontinuation of anti-TNF treatment and last visit in non-responders and responders respectively. Results: The mean age was 55.3±15 and 50±10.8 in the resp-AT and nonresp-AT groups, respectively. The demographic and clinical characteristics of both groups are shown in Table 1 . At baseline, a lower BMI was observed in the resp-AT group (25.6±5 resp-AT, 28.7±5 nonresp-AT, p=0.013); 59% and 35% were in concomitant treatment with DMARDS at baseline in the resp-AT and nonresp-AT groups respectively (p=0.032); 33% of the resp-AT were in monotherapy in the last visit compared to 62% of the nonresp-AT when discontinued the 1st AT (p=0.008). There were no differences in BASDAI (5.6±2 resp-AT, 6.1±1.9 nonresp-AT, p=0.2) and ASDAS (3.3±1.1 resp-AT, 3.4±1.1 nonresp-AT, p=0.8) at baseline. In v-6, the resp-AT group had a better clinical response in terms of BASDAI (3.2±2.3 in resp-AT, 4.7±2.4 in nonresp-AT, p=0.004) and ASDAS (1.7±0.9 in resp-AT, 2.7±1.2 in nonresp-AT, p=0.00), as well as in the delta-ASDAS ( ASDAS) (1.56±1.2 resp -AT, 0.7±0.9 nonresp-AT, p=0.04). However, delta-BASDAI ( BASDAI) showed no difference between the two groups (2.3±2.3 resp-AT, 1.5±1.6 nonresp-AT, p=0.1).
24% of the nonresp-AT were ADA + at drug discontinuation, while only 0.7% of the AT-resp (AT) were ADA + (p=0.00) at last visit. Conclusions: In our cohort of patients with axial SpA, a significant improvement in BASDAI, ASDAS and ASDAS after 6 months of treatment is associated with a lower frequency of drop-out of the first AT. Moreover a lower BMI, DMARDS at baseline and absence of ADA determine a better response to AT treatment. Objectives: To assess the differences in the occurrence of co-morbidities from cardiovascular, respiratory, renal/urological and Central nervous systems (CNS) between patients with spondyloarthritis (SpA) not having headache as presenting symptom and those having headache assuming that those describing headache represent secondary (s) fibromyalgia (FM). (previous submitted abstract provides justification on headache as presenting symptom associated with secondary sFM). Methods: Data obtained through a questionnaire from 776 patients seen in clinic with SpA was analysed with reference to headache as symptom at presentation. From the total 776 patients 13 patients did not record an answer to the question and were hence excluded. The remaining 763 patients were divided in 2 groups: Those having headache at presentation (n=117) considered having sFM, and those not having headache at presentation (n=656). The data of patients with sFM were compared with the data of patients who did not report headache as a presentation symptom therefore not having FM with regards to age, disease duration, delay in diagnosis, disease activity (BASDAI) functional ability (BASFI), ESR, CRP and associated co morbidities from cardiovascular, respiratory, renal/urinary, and CNS systems. Central nervous system was evaluated by symptoms of dizziness and numbness. Independent sample T test was used to explore differences between the 2 groups and confidence intervals obtained. Results: Table shows demographics and disease characteristics as well as differences between SpA patients presenting with headache (indicating secondary FM), and those not presenting with headache. A greater proportion of patients with SpA and headache (sFM) report cardiovascular and CNS co-morbidities. There was no significant difference noted in the respiratory or renal/ urological co-morbidities amongst the 2 sub-groups. Conclusions: A significantly higher proportion of patients described cardiovascular and CNS co-morbidities in the sFM group of SpA. No significant difference was noted in the 2 sub-groups with regards to the respiratory or renal systems. Background: Magnetic resonance imaging (MRI) has become the imaging modality of choice in early SpA. Not only has this imaging technique proven useful in the identification of inflammatory lesions on T2 FS/STIR sequences, also structural lesions such as erosions, sclerosis, fat infiltration and ankylosis can be seen on T1 sequences. There is still ongoing debate concerning the possible inclusion of any structural lesion in the definition of a positive MRI in order to improve specificity. However, erosions and fat infiltration have also been found in respectively more than 10% and 17% of non-SpA patients on MRI of the sacroiliac joints.
[1] Objectives: To evaluate the presence of structural lesions on MRI of the sacroiliac joints (MRI-SIJ) in young, asymptomatic subjects. Methods: Twenty-five military recruits volunteered to perform a MRI-SIJ before and after 6 week of intense physical training, of which 22 recruits underwent imaging at both time points. The MRIs were scored for structural lesions by 3 trained readers MdH, GV and TR, blinded for time sequence and clinical findings. Regarding the number of lesions a consensus was made by agreement of 2 out of 3 readers. Results: At baseline, structural lesions were present in 36.4% (8/22) of subjects of which 5 subjects presented with at least 1 erosion, one subject with sclerosis and 3 subjects presented fatty lesions. This increased to 50% subjects (11/22) with structural lesions on MRI-SIJ after 6 weeks of mechanical stress, of which 8 subjects with at least 1 erosion, one subject with sclerosis and 3 subjects with fatty lesions (P=0.453). The change scores for sclerosis, erosions and fatty lesions were respectively 0.0 (±0.0), 0.2 (±0.1) and 0.3 (±0.2). None of the subjects displayed ankylosis. The lesion distribution is visualized in Table1. 
Conclusions:
Although not prevalent, structural lesions such as erosions, sclerosis and fatty lesions can be found in young asymptomatic subjects. However, these lesions do not seem to increase after 6 week of intense physical training.
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